Download
s41375-021-01386-z.pdf 488,79KB
WeightNameValue
1000 Titel
  • Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
1000 Autor/in
  1. Damaschin, Carla |
  2. Goergen, Helen |
  3. Kreissl, Stefanie |
  4. Plütschow, Annette |
  5. Breywisch, Frank |
  6. Mathas, Stephan |
  7. Meissner, Julia |
  8. Sökler, Martin |
  9. Topp, Max S. |
  10. Vucinic, Vladan |
  11. Zimmermann, Andreas |
  12. von Tresckow, Bastian |
  13. Fuchs, Michael |
  14. Engert, Andreas |
  15. Borchmann, Peter |
  16. Eichenauer, Dennis A. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-08-18
1000 Erschienen in
1000 Quellenangabe
  • 36(2):580-582
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41375-021-01386-z |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807388/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Schizophrenia is a chronic and severe mental disorder that affects over 20 million people worldwide. Common symptoms include distortions in thinking, perception, emotions, language, and self awareness. Different hypotheses have been proposed to explain the development of schizophrenia, however, there are no unifying features between the proposed hypotheses. Schizophrenic patients have perturbed levels of glucose in their cerebrospinal fluid, indicating a disturbance in glucose metabolism. We have explored the possibility that disturbances in glucose metabolism can be a general mechanism for predisposition and manifestation of the disease. We discuss glucose metabolism as a network of signaling pathways. Glucose and glucose metabolites can have diverse actions as signaling molecules, such as regulation of transcription factors, hormone and cytokine secretion and activation of neuronal cells, such as microglia. The presented model challenges well-established concepts in enzyme kinetics and glucose metabolism. We have developed a 'two-cell' model of glucose metabolism, which can explain the effects of electroconvulsive therapy and the beneficial and side effects of olanzapine treatment. Arrangement of glycolytic enzymes into metabolic signaling complexes within the 'two hit' hypothesis, allows schizophrenia to be formulated in two steps. The 'first hit' is the dysregulation of the glucose signaling pathway. This dysregulation of glucose metabolism primes the central nervous system for a pathological response to a 'second hit' via the astrocytic glycogenolysis signaling pathway.
1000 Sacherschließung
lokal Letter
lokal Lymphoma
lokal Clinical Trials, Phase II as Topic/statistics
lokal Neoplasm Recurrence, Local/pathology [MeSH]
lokal Neoplasms, Second Primary/pathology [MeSH]
lokal Cyclophosphamide/administration
lokal Etoposide/administration
lokal Male [MeSH]
lokal Randomized Controlled Trials as Topic/statistics
lokal Bleomycin/administration
lokal Combination drug therapy
lokal Vincristine/administration
lokal Hodgkin Disease/pathology [MeSH]
lokal Adolescent [MeSH]
lokal Female [MeSH]
lokal Follow-Up Studies [MeSH]
lokal Hodgkin Disease/drug therapy [MeSH]
lokal Neoplasms, Second Primary/drug therapy [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Middle Aged [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal Survival Rate [MeSH]
lokal Prognosis [MeSH]
lokal Young Adult [MeSH]
lokal Brentuximab Vedotin/administration
lokal Neoplasm Recurrence, Local/drug therapy [MeSH]
lokal Phase II trials
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/RGFtYXNjaGluLCBDYXJsYQ==|https://frl.publisso.de/adhoc/uri/R29lcmdlbiwgSGVsZW4=|https://frl.publisso.de/adhoc/uri/S3JlaXNzbCwgU3RlZmFuaWU=|https://frl.publisso.de/adhoc/uri/UGzDvHRzY2hvdywgQW5uZXR0ZQ==|https://frl.publisso.de/adhoc/uri/QnJleXdpc2NoLCBGcmFuaw==|https://orcid.org/0000-0001-9626-1413|https://frl.publisso.de/adhoc/uri/TWVpc3NuZXIsIEp1bGlh|https://frl.publisso.de/adhoc/uri/U8O2a2xlciwgTWFydGlu|https://frl.publisso.de/adhoc/uri/VG9wcCwgTWF4IFMu|https://frl.publisso.de/adhoc/uri/VnVjaW5pYywgVmxhZGFu|https://frl.publisso.de/adhoc/uri/WmltbWVybWFubiwgQW5kcmVhcw==|https://frl.publisso.de/adhoc/uri/dm9uIFRyZXNja293LCBCYXN0aWFu|https://frl.publisso.de/adhoc/uri/RnVjaHMsIE1pY2hhZWw=|https://frl.publisso.de/adhoc/uri/RW5nZXJ0LCBBbmRyZWFz|https://frl.publisso.de/adhoc/uri/Qm9yY2htYW5uLCBQZXRlcg==|https://orcid.org/0000-0002-1927-3514
1000 Hinweis
  • DeepGreen-ID: ae72feeaf8734ed2af7b841d47036ea2 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6443794.rdf
1000 Erstellt am 2023-04-27T10:49:57.104+0200
1000 Erstellt von 322
1000 beschreibt frl:6443794
1000 Zuletzt bearbeitet Sat Oct 14 04:33:56 CEST 2023
1000 Objekt bearb. Sat Oct 14 04:33:56 CEST 2023
1000 Vgl. frl:6443794
1000 Oai Id
  1. oai:frl.publisso.de:frl:6443794 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source